Literature DB >> 26279411

Comparison between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: effects on uterine, umbilical and fetal middle cerebral artery pulsatility indices.

A Trapani1, L F Gonçalves2,3, T F Trapani4, M J Franco1, R N Galluzzo1, M M S Pires5.   

Abstract

OBJECTIVES: To evaluate the effects of transdermal nitroglycerin (GTN) and sildenafil citrate on Doppler velocity waveforms of the uterine (UtA), umbilical (UA) and fetal middle cerebral (MCA) arteries in pregnancies with intrauterine growth restriction (IUGR).
METHODS: This was a prospective study of 35 singleton pregnancies (gestational age, 24-31 weeks) with IUGR and abnormal UtA and UA Doppler waveforms. We compared maternal arterial blood pressure and Z-scores of the pulsatility index (PI) of UtA, UA and fetal MCA before and after application of a transdermal GTN patch (average dose, 0.4 mg/h), oral sildenafil citrate (50 mg) or placebo. Statistical analysis was performed by ANOVA for paired samples.
RESULTS: There was a significant decrease in UtA-PI after application of GTN (21.0%) and sildenafil citrate (20.4%). A significant reduction in UA-PI was also observed for both GTN (19.1%) and sildenafil citrate (18.2%). There was no difference in UtA- and UA-PI when the GTN and sildenafil groups were compared. No changes in Doppler velocimetry were observed in the placebo group and no significant change in MCA-PI was observed in any group. Maternal arterial blood pressure decreased with administration of both GTN and sildenafil citrate in those with pre-eclampsia.
CONCLUSION: The use of transdermal GTN or sildenafil citrate in pregnancies with IUGR is associated with a significant reduction in both UtA and UA Doppler PI, as well as maternal arterial blood pressure. Neither drug affected the MCA-PI.
Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Doppler ultrasonography; fetal growth restriction; nitroglycerin; phosphodiesterase inhibitors; sildenafil citrate

Mesh:

Substances:

Year:  2016        PMID: 26279411     DOI: 10.1002/uog.15673

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  5 in total

1.  Maternal low molecular weight heparin versus sildenafil citrate for fetal growth restriction: a randomized, parallel groups, open-label clinical trial.

Authors:  R Rasheedy; G El Bishry; R Tarek
Journal:  J Perinatol       Date:  2019-11-06       Impact factor: 2.521

Review 2.  Treating the dysfunctional placenta.

Authors:  Colin P Sibley
Journal:  J Endocrinol       Date:  2017-05-08       Impact factor: 4.286

3.  Detailed statistical analysis plan for the Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) randomised clinical trial on sildenafil versus placebo for pregnant women with severe early onset fetal growth restriction.

Authors:  Anouk Pels; Janus C Jakobsen; Wessel Ganzevoort; Christiana A Naaktgeboren; Wes Onland; Aleid G van Wassenaer-Leemhuis; Christian Gluud
Journal:  Trials       Date:  2019-01-11       Impact factor: 2.279

4.  Short-term outcomes of phosphodiesterase type 5 inhibitors for fetal growth restriction: a study protocol for a systematic review with individual participant data meta-analysis, aggregate meta-analysis, and trial sequential analysis.

Authors:  Jessica Liauw; Katie Groom; Wessel Ganzevoort; Christian Gluud; Christopher J D McKinlay; Andrew Sharp; Laura Mackay; Chirag Kariya; Ken Lim; Peter von Dadelszen; Jacqueline Limpens; Janus C Jakobsen
Journal:  Syst Rev       Date:  2021-12-03

Review 5.  Placental Ischemia Says "NO" to Proper NOS-Mediated Control of Vascular Tone and Blood Pressure in Preeclampsia.

Authors:  Ana C Palei; Joey P Granger; Frank T Spradley
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.